BG Negev Technologies and Applications, the technology transfer company of Ben Gurion University of the Negev, has raised $1 million from a US private equity fund, to develop therapies for neurodegenerative diseases. The funding will support a study conducted by the university’s Department of Immunology and Microbiology, which might be useful for prolonging lifespans for patients with diseases such as Amyotrophic Lateral Sclerosis (ALS). View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Elbit Sells Air Defense System To Foreign Client For $50M
April 30, 2024
Facebook comments